Research programme: GPBAR1 protein agonists - Intercept Pharmaceuticals

Drug Profile

Research programme: GPBAR1 protein agonists - Intercept Pharmaceuticals

Alternative Names: GPBAR1 protein agonists - Intercept Pharmaceuticals; INT-777; S-EMCA; TGR5 protein agonists - Intercept Pharmaceuticals

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intercept Pharmaceuticals
  • Class Bile acids and salts; Cholanes; Small molecules
  • Mechanism of Action GPBAR1 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Metabolic disorders; Obesity

Most Recent Events

  • 30 Nov 2017 Preclinical development is ongoing for Metabolic disorders, including Diabetes mellitus and Obesity (Intercept Pharmaceuticals Pipeline, November 2017)
  • 05 Dec 2013 GPBAR1 protein agonist INT 777 is available for licensing as of 05 Dec 2013.
  • 09 Aug 2011 Research programme: GPBAR1 protein agonists licensed to Servier worldwide (excluding USA & Japan)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top